We expect Teradyne to maintain a strong balance sheet and continue generating robust free cash flow while keeping minimal to no leverage. As of Dec. 31, 2024, Teradyne held a net cash position, with ...

Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic ...

Learn how Claude 3.7 Sonnet empowers businesses with AI-driven automation, simplifying tasks and boosting productivity ...

Dengue virus, a WHO grade 3 emergency, infected over 10 million individuals in 2024. With no population-effective prophylaxis or direct treatment, there is an urgent need for immediate vector control ...

Reported positive initial data from INSPIRE DUCHENNE trial of next-generation Duchenne gene therapy candidate, SGT-003; In mid-2025, Company plans to request a U.S. Food and Drug Administration ...

Reported positive initial data from INSPIRE DUCHENNE trial of next-generation Duchenne gene therapy candidate, SGT-003; In mid-2025, ...

In February 2024 a putative class action complaint against Molecular Partners, its directors, and certain of its executive officers, originally filed in July 2022 in the U.S. District Court for the ...

Unity Software U shares have lost 9.3% since the company released its fourth-quarter 2024 earnings, creating what appears to ...

Conference Call and Webcast Today at 8:30 a.m. ETReached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical ...